Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Alliance Foundation Trials, LLC. Clear all
Terminated Phase 3 Interventional Results available

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

NCT03498716
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Atezolizumab, Paclitaxel, Dose-dense Doxorubicin or dose-dense Epirubicin, Cyclophosphamide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
2,199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
17
States / cities
Concord, California • Los Angeles, California • St. Helena, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 16, 2026, 10:14 PM EDT
Active, not recruiting Phase 2 Interventional

Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC

NCT05798663
View directory record Official record
Conditions
NSCLC
Interventions
Atezolizumab, Tiragolumab
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
15
States / cities
La Jolla, California • Oakland, California • Roseville, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 16, 2026, 10:14 PM EDT
Terminated Phase 3 Interventional

Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype

NCT05207709
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Ribociclib + Letrozole OR Fulvestrant, Palbociclib + Letrozole OR Fulvestrant, Paclitaxel +/- Tislelizumab
Drug
Lead sponsor
SOLTI Breast Cancer Research Group
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
26
States / cities
Clearwater, Florida • Coral Gables, Florida • Hollywood, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 16, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Results available

Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC

NCT02591615
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
MK-3475, Carboplatin, Paclitaxel, Pemetrexed
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
11
States / cities
La Jolla, California • Chicago, Illinois • Evanston, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Oct 16, 2026, 10:14 PM EDT
Active, not recruiting Phase 2 Interventional Results available

CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer

NCT04062708
View directory record Official record
Conditions
Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
Durvalumab, Surgery, Radiotherapy
Drug · Procedure · Radiation
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
9
States / cities
Chicago, Illinois • Boston, Massachusetts • Lowell, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 16, 2026, 10:14 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

NCT04009109
View directory record Official record
Conditions
Myeloma, Multiple
Interventions
Lenalidomide, Ixazomib, Daratumumab Injection, Dexamethasone
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years to 75 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Bangor, Maine • Boston, Massachusetts • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 16, 2026, 10:14 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

NCT02947685
View directory record Official record
Conditions
HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer
Interventions
palbociclib, trastuzumab, pertuzumab, letrozole, Anastrozole, Exemestane, Fulvestrant
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
35
States / cities
San Francisco, California • Washington D.C., District of Columbia • Clearwater, Florida + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 16, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Results available

Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide

NCT04335682
View directory record Official record
Conditions
Metastatic Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer, Castrate Resistant Prostate Cancer, Hormone Sensitive Prostate Cancer, Non-metastatic Prostate Cancer
Interventions
Darolutamide, Enzalutamide
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older · Male only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
8
States / cities
San Francisco, California • Chicago, Illinois • Fairway, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 16, 2026, 10:14 PM EDT
Completed Phase 1 Interventional Results available

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

NCT03702725
View directory record Official record
Conditions
Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma
Interventions
Ibrutinib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Maywood, Illinois • Boston, Massachusetts • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 16, 2026, 10:14 PM EDT
Active, not recruiting Phase 2 Interventional

Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma

NCT03478514
View directory record Official record
Conditions
Mantle Cell Lymphoma, B Cell Lymphoma
Interventions
Palbociclib, Ibrutinib
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
9
States / cities
Duarte, California • Baltimore, Maryland • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 16, 2026, 10:14 PM EDT
Recruiting Phase 3 Interventional

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

NCT05633654
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Sacituzumab govitecan-hziy (SG), Pembrolizumab, Capecitabine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
188
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 158 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 16, 2026, 10:14 PM EDT
Recruiting Phase 2 Interventional

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

NCT07149363
View directory record Official record
Conditions
Small Cell Lung Cancer (SCLC)
Interventions
Durvalumab 50 MG/ML
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
6
States / cities
Chicago, Illinois • Scarborough, Maine • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 16, 2026, 10:14 PM EDT
Completed Not applicable Interventional Results available

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

NCT02744092
View directory record Official record
Conditions
Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Blood Clot
Interventions
Rivaroxaban, Apixaban, Edoxaban, Dabigatran, Warfarin, Dalteparin, Enoxaparin, Fondaparinux
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
811 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
151
States / cities
Chula Vista, California • Fremont, California • Fresno, California + 104 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 16, 2026, 10:14 PM EDT
Recruiting Not applicable Interventional

Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer

NCT06963723
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer
Interventions
Financial Hardship Screening, Enhanced Usual Care
Other
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
21 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Phoenix, Arizona • Concord, New Hampshire • Manchester, New Hampshire + 3 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 16, 2026, 10:14 PM EDT
Active, not recruiting Phase 3 Interventional Results available

PALbociclib CoLlaborative Adjuvant Study

NCT02513394
View directory record Official record
Conditions
Breast Cancer
Interventions
Palbociclib, Standard Adjuvant Endocrine Therapy
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
5,796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
192
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 138 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 16, 2026, 10:14 PM EDT
Active, not recruiting Not applicable Interventional Results available

Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS

NCT02926911
View directory record Official record
Conditions
DCIS, Ductal Carcinoma in Situ
Interventions
Surgery, Active Monitoring
Other
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
40 Years to 99 Years · Female only
Enrollment
997 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
141
States / cities
Anchorage, Alaska • Phoenix, Arizona • Duarte, California + 117 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 16, 2026, 10:14 PM EDT
Completed Phase 3 Interventional

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

NCT03009981
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide, LHRH Analogue, Abiraterone Acetate, Prednisone
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older · Male only
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
69
States / cities
Phoenix, Arizona • Chula Vista, California • Duarte, California + 58 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 16, 2026, 10:14 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer

NCT02967133
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent
Interventions
Nivolumab, nab-paclitaxel
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Edgewood, Kentucky • Saint Louis Park, Minnesota • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Oct 16, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Results available

Atezolizumab Immunotherapy in Patients With Advanced NSCLC

NCT03102242
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Atezolizumab
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years to 99 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
13
States / cities
Phoenix, Arizona • La Jolla, California • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 16, 2026, 10:14 PM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer

NCT02963090
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Topotecan, Pembrolizumab
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Saint Louis Park, Minnesota • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 16, 2026, 10:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Electronic Patient Reporting of Symptoms During Cancer Treatment

NCT03249090
View directory record Official record
Conditions
Metastatic Cancer
Interventions
Patient Self-Reporting of Symptoms, Usual Care Delivery
Other
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
21 Years and older
Enrollment
1,197 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
45
States / cities
Grand Junction, Colorado • Lawrenceville, Georgia • Harvey, Illinois + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 16, 2026, 10:14 PM EDT
Active, not recruiting Phase 3 Interventional

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

NCT04720157
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
1,140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
70
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 16, 2026, 10:14 PM EDT
Terminated Phase 1 Interventional

Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease

NCT03656627
View directory record Official record
Conditions
Autoimmune Diseases, Non-small Cell Lung Cancer, Rheumatoid Arthritis, Psoriasis, Giant Cell Arteritis, Polymyalgia Rheumatica, Systemic Lupus Erythematosus, Crohn Disease, Multiple Sclerosis, Ulcerative Colitis
Interventions
Nivolumab
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Chicago, Illinois • Boston, Massachusetts • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 16, 2026, 10:14 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

NCT04486352
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Atezolizumab - 28 Day Cycle, Bevacizumab, Ipatasertib, Talazoparib, Trastuzumab emtansine, Tiragolumab, Atezolizumab - 21 Day Cycle, Inavolisib, Letrozole, Giredestrant, Abemaciclib
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older · Female only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
21
States / cities
Duarte, California • San Francisco, California • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 16, 2026, 10:14 PM EDT